BioHarvest Sciences Inc.

About BioHarvest Sciences Inc.

BioHarvest Sciences is a pioneering biotech company focused on revolutionizing biologics through its proprietary Botanical Synthesis technology. Founded in 2007 in Israel, the company aims to improve human health by marrying science with nature, developing plant-based small and complex molecules for pharmaceutical, nutraceutical, cosmeceutical, and nutrition sectors. Their mission emphasizes sustainability, health, and wellness, targeting an aging population seeking natural solutions.

Products & Services

VINIA®:A flagship red grape cell product containing a full spectrum of polyphenols, including Piceid Resveratrol, designed to boost nitric oxide production, increase blood flow, and enhance energy and circulation.

Nutraceuticals:Plant-based health products under development using the same direct-to-consumer subscription strategies as VINIA®.

CDMO Services:Contract Development and Manufacturing Organization services allowing industry partners to leverage Botanical Synthesis technology for proprietary plant-based molecules in pharmaceutical, nutraceutical, cosmeceutical, and nutrition sectors.

Therapeutic Solutions:Innovative plant-based compositions targeting specific health indications, including brain, heart, optic, and sexual health, with ongoing clinical trials.

Specialties

Botanical Synthesis Technology Plant-Based Molecules Biologics Nutraceuticals Pharmaceuticals Cosmeceuticals Sustainability

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant (non-dilutive loan) T: - FT: Grant (non-dilutive loan)	A: 1600000 MR: - FA: $1.6 million FAN: 1600000	D: 2025-12-18 FD: 2025-12-18	1 investors
2	RT: Public Offering T: - FT: Public Offering	A: 19900000 MR: - FA: $19.9 million FAN: 19900000	D: 2025-11-10 FD: 2025-11-10	1 investors
3	RT: Public Offering T: - FT: Public Offering	A: 17400000 MR: - FA: 17.4 million FAN: 17400000	D: 2025-11-07 FD: 2025-11-07	1 investors
4	RT: Convertible Debt and Equity T: - FT: Convertible Debt and Equity	A: 10900000 MR: - FA: $10.9 Million FAN: 10900000	D: 2025-09-22 FD: 2025-09-22	1 investors
5	RT: Private Placement T: - FT: Private Placement	A: 4329982 MR: - FA: 4,329,982.62 FAN: 4329982	D: 2024-06-28 FD: 2024-06-28	-
6	RT: Private Placement T: - FT: Private Placement	A: 5000000 MR: - FA: up to USD $5,000,000 FAN: 5000000	D: 2024-06-21 FD: 2024-06-21	-
7	RT: Convertible Notes T: - FT: Convertible Notes	A: 8000000 MR: - FA: up to CAD $8M FAN: 8000000	D: 2023-02-21 FD: 2023-02-21	-

Grant (non-dilutive loan) Latest

2025-12-18

$1.6M

1 investor (Pro only)

Public Offering 2025-11-10

$19.9M

Public Offering 2025-11-07

$17.4M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

I

Ilan Sobel

CEO

Y

Yochi Hagay

CTO

Z

Zaki Rakib

Chairman Of The Board

I

Ilana Belzer

Chief Operating Officer

M

Malkit Azachi

VP R&D

M

Michal Sapir

VP Regulation Affairs

View 22 more team members with Pro

Unlock Full Team Directory

Recent News